Adamas Pharma (ADMS): Reiterating Buy Ahead Of World Parkinson Congress - Mizuho

September 22, 2016 9:04 AM EDT
Get Alerts ADMS Hot Sheet
Price: $14.64 +0.34%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 28 | New: 38
Trade ADMS Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Adamas Pharmaceuticals (NASDAQ: ADMS) ahead of the company's presentation at the World Parkinson Congress this week. The company will be presenting:

1) The full results of its Phase III EASE-LID 3 study that demonstrated a 1.9 hour improvement in ON time without troublesome dyskinesia, and a 1.1 hour decrease in OFF time, collectively providing the patient with 3 hours of symptom relief per day

2) A post-hoc analysis of the Phase III EASE-LID trial that demonstrated directionally positive improvements in all 10 activities of daily living (ADL).

At the end of 12 weeks, patients that received ADS-5102 demonstrated the most positive directional improvements in scores for public and social settings, walking and balance, exciting or emotional settings, and eating tasks. Approximately 46-72% of patients reported impairment on these activities at baseline.

The analyst is encouraged by the improvement in the walking and balance score which may be a positive read-through for the company's second ADS-5102 program in MS Gait. No change to the price target of $26.

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $17.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Irina Koffler

Add Your Comment